Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 611 to 620 of 2733 total matches.
Fluvoxamine for COVID-19?
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
for treatment of COVID-19,1 and several
monoclonal antibodies have been granted emergency
use authorizations ...
A recent article in JAMA and an interview of its senior
author on 60 Minutes have heightened interest in
off-label use of the oral selective serotonin reuptake
inhibitor (SSRI) fluvoxamine (Luvox, and generics) to
treat COVID-19.
In Brief: A New OTC Naloxone Nasal Spray (RiVive)
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
) product for emergency
treatment of opioid overdose.1 Two 4-mg naloxone
nasal spray formulations, Narcan ...
The FDA has approved RiVive (Harm Reduction
Therapeutics), a 3-mg naloxone nasal spray, as
an over-the-counter (OTC) product for emergency
treatment of opioid overdose. Two 4-mg naloxone
nasal spray formulations, Narcan and one of its
generics, were approved for OTC sale in 2023.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):47-8 doi:10.58347/tml.2024.1698d | Show Introduction Hide Introduction
In Brief: Erzofri — Another Once-Monthly Paliperidone Formulation (online only)
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024 (Issue 1713)
formulations of
paliperidone palmitate are also available (see Table 1).1
Table 1. Paliperidone Palmitate ...
The FDA has approved Erzofri (Luye), an extended-release
injectable formulation of the second-generation
antipsychotic drug paliperidone palmitate,
for treatment of schizophrenia and schizoaffective
disorder in adults. It is the second once-monthly
formulation of paliperidone palmitate to be approved
in the US for these indications; Invega Sustenna was
the first. Longer-acting injectable formulations of
paliperidone palmitate are also available (see Table 1).
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e171 doi:10.58347/tml.2024.1713j | Show Introduction Hide Introduction
Metaglip and Avandamet for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Dec 23, 2002 (Issue 1146)
DIABETES
Drug Tablet strength Usual daily dosage Cost
1
Metformin − average generic price 500 mg 1500 ...
Two new fixed-dose combinations are now available for management of type 2 diabetes. Metaglip (Bristol-Myers Squibb), a combination of metformin and glipizide, is approved for initial therapy or as second-line treatment when control is not adequate on metformin or a sulfonylurea alone. Avandamet (GlaxoSmithKline), a combination of metformin and rosiglitazone, is approved by the FDA only as second-line therapy for patients who are not well controlled on metformin alone, or are already taking both metformin and rosiglitazone. Glucovance (Bristol-Myers Squibb), a combination of metformin and...
Once-Daily Mesalamine (Lialda) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 26, 2007 (Issue 1257)
not reach the colon.
1
Asacol tablets are coated
with a pH-sensitive film that protects mesalamine ...
A once-daily oral formulation of mesalamine (Lialda - Shire) was recently approved by the FDA for induction of remission in patients with mild to moderate ulcerative colitis.
Oritavancin (Orbactiv) for Skin and Skin Structure Infections
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
to be marketed in the US; telavancin (Vibativ)
and dalbavancin (Dalvance) were approved earlier.1,2
Oritavancin ...
The FDA has approved oritavancin (Orbactiv – The
Medicines Company), a long-acting lipoglycopeptide
antibiotic given as a single intravenous (IV) dose, for
treatment of acute bacterial skin and skin structure
infections caused by susceptible gram-positive
bacteria in adults. It is the third lipoglycopeptide
antibiotic to be marketed in the US; telavancin (Vibativ)
and dalbavancin (Dalvance) were approved earlier.
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
of anal blockage
or incomplete evacuation, and a need for manual
maneuvers to aid defecation.1 ...
The FDA has approved the 5-HT4 receptor agonist
prucalopride (Motegrity – Shire) for treatment of chronic
idiopathic constipation (CIC) in adults. Prucalopride is
the only drug currently approved in the US for treatment
of CIC that stimulates colonic peristalsis. It has been
available in Europe and Canada for several years.
Atogepant (Qulipta) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
in the US for this indication; the first was
rimegepant (Nurtec ODT), which is also approved
for acute treatment of migraine.1 ...
Atogepant (Qulipta – Abbvie), an oral small-molecule
calcitonin gene-related peptide (CGRP) receptor
antagonist ("gepant"), has been approved by the
FDA for prevention of episodic migraine in adults. It
is the second oral CGRP receptor antagonist to be
approved in the US for this indication; the first was
rimegepant (Nurtec ODT), which is also approved
for acute treatment of migraine. Parenteral CGRP
monoclonal antibodies are approved for prevention
of migraine (see Table 3).
Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022 (Issue 1646)
for treatment of
nAMD and DME (see Table 2).1,2
Pronunciation Key
Faricimab: far ik’ i mab Vabysmo: vah buys ...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor
of both vascular endothelial growth factor (VEGF)
and angiopoietin-2 (Ang-2), has been approved by
the FDA for intravitreal treatment of neovascular
(wet) age-related macular degeneration (nAMD) and
diabetic macular edema (DME). It is the first drug to
become available in the US that targets two pathways
involved in maintaining vascular homeostasis.
Several VEGF inhibitors are available for treatment of
nAMD and DME (see Table 2).
Lumateperone (Caplyta) for Adjunctive Treatment of Depression
The Medical Letter on Drugs and Therapeutics • Feb 02, 2026 (Issue 1747)
was approved earlier for treatment of schizophrenia
and bipolar depression.1,2
ADJUNCTIVE TREATMENT ...
The FDA has approved the second-generation
antipsychotic drug lumateperone (Caplyta — Intra-Cellular Therapies) for adjunctive treatment of major
depressive disorder (MDD) in adults. Lumateperone
was approved earlier for treatment of schizophrenia
and bipolar depression.
Med Lett Drugs Ther. 2026 Feb 2;68(1747):20-2 doi:10.58347/tml.2026.1747c | Show Introduction Hide Introduction
